Topic 108

cancer tumor proliferation biology growth cancers cells therapeutic inhibition signaling cell oncogenic progression expression survival tumors pathway activation promotes inhibitors metastasis breast tumorigenesis target lines treatment inhibitor targeting apoptosis suppressor vivo kinase resistance mediated therapy mechanistically induced migration oncogene knockdown malignant dependent myc inhibiting invasion loss drives transcription poor akt pro xenograft prognosis aggressive carcinoma factor tumorigenic transcriptional activity upregulation anti mechanism receptor vitro patients p53 depletion metastatic leukemia therapies driven regulates through overexpression inhibited melanoma mapk arrest via activated pathways prostate proliferative tumour promote driver adenocarcinoma death enhanced cycle promoting induces decreased targeted apoptotic levels activating protein reduced downstream

366 items. Top items listed below.

P4HA2 is associated with prognosis, promotes proliferation, invasion, migration and EMT in glioma 98 14 3

PD-L1 lncRNA splice promotes lung adenocarcinoma progression via enhancing c-Myc activity 108 14 10 3

Induction of intracellular wild-type p53 amyloids leading to cellular transformation and tumor formation in mice 142 108 14 3

Abl kinase deficiency promotes AKT pathway activation and prostate cancer progression and metastasis 108 14 10 3

RIPK2 Stabilizes c-Myc and is an Actionable Target for Inhibiting Prostate Cancer Metastasis 108 14 10 3

UBR-Box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target 108 14 3

UHRF1 drives the poor prognosis associated with RB loss in osteosarcoma 108 14 3

ELP-dependent expression of MCL1 promotes resistance to EGFR inhibition in triple-negative breast cancer cells 108 14 3

Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling 108 14 3

AMPK-Fyn signaling promotes Notch1 stability to potentiate hypoxia-induced breast cancer stemness and drug resistance 108 102 14 3

Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers 126 14 10 3

Cyclin G2 inhibits oral squamous cell carcinoma growth and metastasis by binding to insulin-like growth factor binding protein 3 and regulating the FAK-SRC-STAT signaling pathway 108 14 10 3

ISL2 is an epigenetically silenced tumor suppressor and regulator of metabolism in pancreatic cancer 108 14 3

TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway 98 14 3

HDAC and MAPK/ERK inhibitors cooperate to reduce viability and stemness phenotype in medulloblastoma 186 108 14 10 3

Nuclear Transport Factor 2 (NTF2) suppresses metastatic melanoma by modifying cell migration, metastasis, and gene expression 108 14 3

Oncogenic GLI1 and STAT1/3 activation drives immunosuppressive tryptophan/kynurenine metabolism via synergistic induction of IDO1 in skin cancer cells 108 14 10 3

WSB1 Regulates c-Myc Expression Through β-catenin Signaling and Forms a Feedforward Circuit Promoting the Development of Cancer. 108 14 3

Epigenetic downregulation of HER2 during EMT leads to tumor resistance to HER2-targeted therapies in breast cancer 98 14 10 3

Loss of CPAP expression promotes sustained EGFR signaling and Epithelial-Mesenchymal Transition in oral cancer cells 98 14 3

HDAC3 regulates senescence and lineage-specific transcriptional programs in non-small cell lung cancer 142 108 14 3

NFATC4 Promotes Quiescence and Chemotherapy Resistance in Ovarian Cancer 108 14 3

YAP and β-catenin co-operate to drive oncogenesis in basal breast cancer 108 14 3

IWS1 phosphorylation promotes cell proliferation and predicts poor prognosis in EGFR mutant lung adenocarcinoma patients, through the cell cycle-regulated U2AF2 RNA splicing. 108 14 3

Identification of PIM1 substrates reveals a role for NDRG1 in prostate cancer cellular migration and invasion 108 102 14 3

The Oncogenic Function of PLAGL2 is Mediated via Specific Target Genes Through a Wnt-independent Mechanism in Colorectal Cancer 142 108 14 3

Loss of hepatic aldolase B activates Akt and promotes hepatocellular carcinogenesis by destabilizing Aldob/Akt/PP2A protein complex 108 14 3

Deletion and overexpression of the scaffolding protein IQGAP1 promotes HCC 108 14 3

SREBP1 regulates mitochondrial metabolism in oncogenic KRAS expressing NSCLC 108 95 14 3

A non-canonical EZH2 function sensitizes solid tumors to genotoxic stress 142 108 14 3

Gamma secretase inhibitors inhibit ovarian cancer development and enhance olaparib's anti-ovarian cancer activity and its mechanism 126 108 14 10 3

Sustained Androgen Receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis 108 14 10 3

ADAR1 editing dependency in triple-negative breast cancer 108 14 3

RNF40-dependent epigenetic regulation of actin cytoskeletal dynamics is required for HER2-driven mammary tumorigenesis 142 108 14 3

Therapy-induced transdifferentiation promotes glioma growth independent of EGFR signaling 108 14 10 3

Transcriptional control of DNA repair networks by CDK7 regulates sensitivity to radiation in Myc-driven Medulloblastoma 108 14 3

The lysosomal TRPML1 channel promotes breast cancer survival by supporting mitochondrial function and cellular metabolism 95 14 3

An NKX2-1/ERK/WNT feedback loop modulates gastric identity and response to targeted therapy in lung adenocarcinoma 108 14 3

KMT2D Links TGF-β Signalling to Non-Canonical Activin Pathway and Regulates Pancreatic Cancer Cell Plasticity 98 14 3

HSATII RNA is induced via a non-canonical ATM-regulated DNA-damage response pathway and facilitates tumor cell proliferation and movement 108 14 3

Integrated genomics and comprehensive validation reveal novel drivers of genomic evolution in esophageal adenocarcinoma 14 9 3

Obesity-driven changes in ECM composition promote local invasion and metastasis of breast tumors 14 10 3

Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance 126 14 10 3

A Drosophila model of oral peptide therapeutics for adult intestinal stem cell tumors 142 108 14 3

BET inhibition induces an anti-apoptotic adaptive response and therapeutic vulnerability to MCL1 inhibitors in breast cancer 108 14 10 3

STIL a novel link in Shh and Wnt signaling, endowing oncogenic and stem like attributes to colorectal cancer 108 14 3

The MSP-RON axis stimulates cancer cell growth in models of triple negative breast cancer 108 14 10 3

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit 108 14 10 3

PLEKHA4 Promotes Wnt/β-catenin Signaling-Mediated G1/S Transition and Proliferation in Melanoma 108 14 3

Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer 126 108 14 10 3

Time-resolved profiling reveals ATF3 as a novel mediator of endocrine resistance in breast cancer 108 14 3

Tumor -Associated MUC1 Regulates TGF-β Signaling and Function in Pancreatic Ductal Adenocarcinoma 108 14 3

Hypersilencing of SRRM4 suppresses basal microexon inclusion and promotes tumor growth across cancers 142 108 14 3

Beta 1 Integrin Signaling Mediates Pancreatic Ductal Adenocarcinoma Resistance to MEK Inhibition 126 108 14 10 3

The critical role of HDAC1 activates NSCLC growth by nicotine resistance Cisplatin 108 14 3

Double-targeted knockdown of miR-21 and CXCR4 inhibits malignant glioma progression by suppression of the PI3K/AKT and Raf/MEK/ERK pathways 108 14 10 3

Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition 108 14 10 3

LZTR1 inactivation promotes MAPK/ ERK pathway activation in glioblastoma by stabilizing oncoprotein RIT1 108 102 14 3

Cyclic pentapeptide cRGDfK enhances the inhibitory effect of sunitinib on TGF-β1-induced epithelial-to-mesenchymal transition in human non-small cell lung cancer cells 98 14 10 3

Oncogenic H-Ras Signaling Differentially Targets Replicative and Specialized DNA Polymerases for Depletion 7 3

MaTAR25 LncRNA Regulates the Tensin1 Gene to Impact Breast Cancer Progression 108 14 3

PTPN11/SHP2 negatively regulates growth in breast epithelial cells: implications on tumorigenesis 108 14 3

A cell competition-based drug screen identifies a novel compound that induces dual c-Myc depletion and p53 activation 108 14 10 3

Store Independent Ca2+ Entry Regulates the DNA Damage Response in Breast Cancer Cells 108 14 10 3

ATM inhibition drives metabolic adaptation via induction of macropinocytosis 108 14 3

TMIGD1, a putative tumor suppressor, induces G2-M cell cycle checkpoint arrest in colon cancer cells 108 14 3

Targeting the oncogene LSF with either the small molecule inhibitor FQI1 or siRNA causes mitotic delays with unaligned chromosomes, resulting in cell death or senescence 108 14 10 3

Loss of Caspase-8 function in combination with SMAC mimetic treatment sensitizes Head and Neck Squamous Carcinoma to radiation through induction of necroptosis 126 108 14 10 3

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers 138 126 14 10 3

Amyloid aggregates accumulate in melanoma metastasis driving YAP mediated tumor progression 108 14 3

Splice-switching of the insulin receptor in rhabdomyosarcoma: Rescuing the IR-B isoform for better treatment options. 108 14 3

PPP6C negatively regulates oncogenic ERK signaling through dephosphorylation of MEK 186 102 14 3

Decorin, a novel negative modulator of E-cadherin in inflammatory breast cancer 108 7 3

Vitexin inhibited the invasion, metastasis, and progression of human melanoma cells by targeting STAT3 signaling pathway 108 14 10 3

Iron and lipocalin-2 modulate cellular responses in the tumor micro-environment of pancreatic ductal adenocarcinoma 98 14 10 3

Plexin-B1 mutation drives prostate cancer metastasis 108 14 3

IER5, a DNA-damage response gene, is required for Notch-mediated induction of squamous cell differentiation 142 108 14 3

Estrogen controls mTOR signaling and mitochondrial function via WNT4 in lobular carcinoma cells 108 14 3

Gain-of-function CRISPR screens identify tumor-promoting genes conferring melanoma cell plasticity and therapy-resistance 108 14 3

The PD-L1/PD-1 Axis Blocks Neutrophil Cytotoxicity In Cancer 197 27 14 10 3

A SNAI2-PEAK1 stromal axis drives progression and lapatinib resistance in HER2-positive breast cancer by supporting a cytokine expression profile that converges on PI3K/Akt signaling 14 3

USP19 modulates cancer cell migration and invasion and acts as a novel prognostic marker in patients with early breast cancer 108 14 3

CK1 Delta Is an mRNA Cap-Associated Protein That Drives Translation Initiation and Tumor Growth 108 14 3

Enhanced inflammatory response mediated by parenchymal cells associates with resistance towards mTOR inhibition 108 14 10 3

Recurrent human papillomavirus-related head and neck cancer undergoes metabolic re-programming and is driven by oxidative phosphorylation 108 14 10 3

A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer 108 14 3

Stromal Amyloid β drives Neutrophil extracellular trap formation to augment tumour growth 14 10 3

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis 126 108 14 10 3

Cancer-specific loss of TERT activation sensitizes glioblastoma to DNA damage 108 14 3

Suppression of p16 alleviates the senescence-associated secretory phenotype 108 14 3

RAL GTPases mediate EGFR/MAPK signalling-driven intestinal stem cell proliferation and tumourigenesis upstream of RAS activation. 108 3

Inhibition of nonsense-mediated decay rescues functional p53β/γ isoforms in MDM2-amplified cancers 108 14 3

A novel role for the tumor suppressor gene ITF2 in lung tumorigenesis and chemotherapy response 186 14 9 3

SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors 126 14 10 3

ATM Inhibition Synergizes with Fenofibrate in High Grade Serous Ovarian Cancer Cells 126 14 10 9 3

Notch1 regulates breast cancer stem cell function via a non-canonical cleavage-independent pathway 108 14 3

Silencing of oncogenic KRAS by mutant-selective small interfering RNA 108 14 3

Id proteins promote a cancer stem cell phenotype in triple negative breast cancer via negative regulation of Robo1 108 14 3

Antibiotic-induced disturbances of the gut microbiota result in accelerated breast tumour growth via a mast cell-dependent pathway 108 14 10 3

Mutant p53 suppresses innate immune signaling to promote tumorigenesis 108 102 3